|
|
Blood, 1 January 2007, Vol. 109, No. 1, pp. 4-5.
 Previous Article | Table of Contents | Next Article 
HEMOSTASIS
Comment on Crow et al, page 155
IVIg in ITP: no role for cytokines?
Bethan Psaila, and
James B. Bussel
WEILL-CORNELL MEDICAL COLLEGE
In this issue of Blood, Crow and colleagues demonstrate that numerous cytokines have no effect whatsoever on the acute platelet response to IVIg in a mouse model of ITP. This suggests that while IVIg may alter expression of immunomodulatory cytokines, these do not directly participate in the acute phase of the mechanism of effect. Why is this important?
Central to the immunopathology of immune thrombocytopenic purpura (ITP) is the destruction of antibody-coated platelets by Fc R-bearing phagocytic cells. The first steps towards elucidating IVIg's therapeutic mechanism came in 1982, when Fehr used chromium-labeled red cells to show that IVIg inhibited clearance of IgG-coated red cells, and inferred that opsonized platelet consumption was also decreased.1 Four years later, specific inhibition of FcR-mediated phagocytosis with an anti-FcRIII antibody in patients with refractory ITP simulated the dramatic but transient platelet response to IVIg.2 Until recently, and despite many speculations, the molecular mechanisms underlying the FcR-mediated response remained unclear.
The field exploded with the characterization of the FcR family and the availability of knock-out and knock-in mouse models. In 2001, Samuelsson and colleagues in Ravetch's laboratory reported that the inhibitory FcR, FcRIIB, was a prerequisite for the platelet response to IVIg in a murine model of ITP.3 This raised new questions: what was the nature of the interactions with FcRIIB, and which cells were involved?
Lazarus' group then dissected the mechanism of action of IVIg through an elegant series of preclinical studies, including the current report. They confirmed that FcRIIB is a prerequisite for the IVIg effect in the passive-sensitization ITP model. Surprisingly, signal transduction molecules (eg, SHIP) did not abrogate the IVIg effect when mutated. Recently, they showed that dendritic cells preincubated with IVIg in vitro could recapitulate the therapeutic effect of IVIg and ameliorate murine ITP. These IVIg-primed leukocytes had effect only when the recipient mouse expressed FcRIIB, whereas FcRIIB was not required on the "initiator" dendritic cells; thus, FcRIIB is not the direct target of IVIg, but is important downstream.4 Moreover, the effect of IVIg was a consequence of IVIg driving activating FcR chain signaling, although the FcR itself was not required.
Nearly simultaneously, Ravetch's group demonstrated that the FcRIIB-mediated effect of IVIg depended entirely on sialylated IVIg. Sialylated-enriched IVIg was 10-fold more efficacious than normal IVIg.5 As nonsialylated IgG is unable to bind FcR, this is consistent with Lazarus' demonstration of FcR signaling on dendritic cells as necessary for the IVIg effect.
The current study explores the role of multiple cytokines and complement pathway components in IVIg-induced dendritic cell FcR signaling activation. None appears to influence the IVIg effect, including, specifically, interleukin-1 receptor antagonist (IL-1Ra).
Lazarus and colleagues' (and Ravetch and colleagues') studies lay the foundation for development of modified IVIg or other novel agents to replace IVIg. One important caveat is that in human ITP, cytokines triggered by infusion of IVIg may affect secretion of antiplatelet antibody or, via FcRn interaction, accelerate its elimination.6 Furthermore, cytokine modulation may be more important in the later phases of the therapeutic response, and these effects are not captured in the acute murine disease model.
Unraveling the mechanism of the effect of IVIg in autoimmune disease, in particular on antibody-mediated platelet clearance, promises to lead to further therapeutic advances in the near future.
Footnotes
Dr Bussel receives clinical research support from Amgen, Biogen-IDEC, Cangene, Genentech, GlaxoSmithKline, and Sysmex, and participates in Baxter's speaker's bureau program. Dr Psaila declares no competing financial interests. 
References
- Fehr J, Hofmann V, Kappeler U. Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin. N Engl J Med 1982; 306:1254–1258.[Abstract]
- Clarkson SB, Bussel JB, Kimberly RP, Valinsky JE, Nachman RL, Unkeless JC. Treatment of refractory immune thrombocytopenic purpura with an anti-Fc gamma-receptor antibody. N Engl J Med 1986; 314:1236–1239.[Medline]
[Order article via Infotrieve]
- Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001; 291:484–486.[Abstract/Free Full Text]
- Siragam V, Crow AR, Brinc D, Song S, Freedman J, Lazarus AH. Intravenous immunoglobulin ameliorates ITP via activating Fc gamma receptors on dendritic cells. Nat Med 2006; 12:688–692.[CrossRef][Medline]
[Order article via Infotrieve]
- Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation Science. 2006; 313:670–673.
- Hansen RJ and Balthasar JP. Intravenous immunoglobulin mediates an increase in anti-platelet antibody clearance via the FcRn receptor. Thromb Haemost 2002; 88:898–899.[Medline]
[Order article via Infotrieve]
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Article in Blood Online:
-
A role for IL-1 receptor antagonist or other cytokines in the acute therapeutic effects of IVIg?
- Andrew R. Crow, Seng Song, John W. Semple, John Freedman, and Alan H. Lazarus
Blood 2007 109: 155-158.
[Abstract]
[Full Text]
[PDF]
|
|
